All infliximab biosimilars are classified as therapeutically equivalent and interchangeable for the FDA-approved indications. The most economical biosimilar product will be utilized based on cost and reimbursements at the time.

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

Formulary, Restricted:

• Administration should be deferred to the outpatient settings. inFLIXimab may be used in the outpatient medical departments.
• Inpatient exception - rare situations where inFLIXimab would be given pre-surgery for cases of ulcerative colitis or Crohn's disease, or long-term patient who has not responded to other options.
• inFLIXimab is approved for use in the treatment of Kawasaki Disease in inpatient and outpatient.
• inFLIXimab is approved for inpatient use in the treatment of steroid refractory immunotherapy-induced colitis in inpatient and outpatient.

Dose Rounding: For inFLIXimab product, round dose nearest 50 mg for patients 18 years and over.

Infliximab-qbtx (IXIFI) Spotlight.pdf

Drug Alert: Inflectra Medication Guide

Drug Alert: Remicade Medication Guide

Drug Alert: Renflexis Medication Guide